甲磺酸乐伐替尼 (LEN) 是一种口服酪氨酸激酶抑制剂，用于治疗各种癌症，包括肝细胞癌 (HCC)。 LEN 治疗 HCC 的不良事件发生率非常高。本研究旨在通过分析 LEN 治疗的 HCC 患者的临床实验室数据，探讨 LEN 诱发的掌跖红肿感觉综合征 (PPES) 的发生率及其与患者人口统计学的关系。这是一项针对患者的单中心回顾性研究2018年4月19日至2020年9月30日期间接受LEN的HCC患者。观察期为LEN给药开始前1周至给药结束后1个月。总共入组了75名HCC患者。 48.0%（36/75 名患者）发现 LEN 诱导的 PPES。在这些患者中，碱性磷酸酶（ALP）、γ-谷氨酰转肽酶（γ-GTP）和单核细胞（MONO）显着升高（ALP：p = 1.32 × 10-3，γ-GTP：p = 4.25 × 10-3，单声道：p = 0.013）。 LEN 诱导的 PPES 的 ALP、γ-GTP 和 MONO 的截止值估计分别为 573U/L、89U/L 和 310 个计数/μL。在多变量分析中，γ-GTP 和 MONO 是 LEN 诱发 PPES 的独立危险因素。高 γ-GTP 和高 MONO 是 LEN 诱发 PPES 的危险因素。© 2024 作者。约翰·威利出版的癌症医学

Lenvatinib mesylate (LEN) is an oral tyrosine kinase inhibitor used to treat various cancers, including hepatocellular carcinoma (HCC). HCC treatment with LEN is associated with a very high incidence of adverse events. This study was aimed at investigating the incidence of LEN-induced palmar-planter erythrodysesthesia syndrome (PPES) and its relationship with patient demographics by analyzing clinical laboratory data of LEN-treated patients with HCC.This was a single-centre, retrospective study of patients with HCC who received LEN between April 19, 2018, and September 30, 2020. The observation period was from 1 week before the start of LEN administration to 1 month after the end of administration.Overall, 75 patients with HCC were enrolled. LEN-induced PPES was found in 48.0% (36/75 patients). In these patients, alkaline phosphatase (ALP), γ-Glutamyl transpeptidase (γ-GTP) and monocytes (MONO) were significantly high (ALP: p = 1.32 × 10-3, γ-GTP: p = 4.25 × 10-3 and MONO: p = 0.013). The cut off values of ALP, γ-GTP and MONO for LEN-induced PPES were estimated at 573 U/L, 89 U/L, and 310 counts/μL, respectively. In the multivariate analysis, γ-GTP and MONO were independent risk factors for LEN-induced PPES.High γ-GTP and high MONO were risk factors for LEN-induced PPES.© 2024 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd.